Skip To Main Content
Barzin Y. Nabet on Muck Rack

Barzin Y. Nabet

As seen in: Nature, Science Magazine, BioRxiv, Cell Press, The Journal of Clinical Investigation, Cancer Discovery, Texas Medical Center
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barzin Y.

Contact Barzin Y., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Loss of the autoimmune risk gene TREX1 reveals a convergence of mechanisms promoting immune tolerance loss and antitumor immunity

|
By Valdemar Priebe, Peter Sheridan Dodds, Mohammad A Saad, Junghyun Lim, Katherine Williams, Stephanie Mittman, Patricia Sanchez, Patricia Sánchez Verified, Ryan Rodriguez, Annie Ogasawara, Grace Barnett, Mayra Cruz Tleugabulova, Barzin Y. Nabet, Jeffrey Hung, Kevin Marroquín, Shari Lau, Serena Lee, Paul J Tyler, Elizabeth Carbone, Herman Gill, Bridget Hough, Janice Corpuz, Haruka Murota, Edward Dere, Smadar Shiffman, Leah K. Schutt
| Science Magazine Verified
Abstract Checkpoint inhibitors targeting PD-1 and CTLA-4 have transformed cancer therapy. Both are genetically associated with autoimmune disorders. Moreover, certain immune-related adverse events and autoimmune risk variants are linked to the clinical efficacy of checkpoint inhibition. These associations suggest common principles governing successful cancer immunotherapy and autoimmune susceptibility.
Open in Who Shared Issue with article?

"Immune Heterogeneity in Small-Cell Lung Cancer and Vulnerability to Im" by Barzin Y Nabet, Habib Hamidi et al.

|
By Barzin Y. Nabet
| Texas Medical Center
10.1016/j.ccell.2024.01.010 Humans, Lung Neoplasms, Immune Checkpoint Inhibitors, Small Cell Lung Carcinoma, Carboplatin, Etoposide, Immunotherapy, IMpower133, atezolizumab, immune checkpoint blockade, immunotherapy, molecular subtyping, small cell lung cancer, transcriptomics, tumor-associated macrophages yes Nabet, Barzin Y; Hamidi, Habib; Lee, Myung Chang; et al., "Immune Heterogeneity in Small-Cell Lung Cancer and Vulnerability to Immune Checkpoint Blockade" (2024).
Open in Who Shared Issue with article?

NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING

|
By Yoo Sun Kim, Barzin Y. Nabet, Briana N Cortez, Nai-Yun Sun
| The Journal of Clinical Investigation
Abstract Downregulation of antigen presentation and lack of immune infiltration are defining features of small cell lung cancer (SCLC), limiting response to immune checkpoint blockade (ICB). While a high–MHC class I, immune-inflamed subset benefits from ICB, underlying mechanisms of immune response in SCLC have yet to be elucidated.
Open in Who Shared View Duplicates (2) Issue with article?
See all 22 articles